Roshan Raja, DO
Neurology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 9
- 3 carriers
- Office
- 1
Offices
1 location · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Plans that list them
9 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Raja’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
9 of 9 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
Medicaid work
$272,449 in 2024
Medicaid paid $272,449 for 2,560 billed services this clinician did in 2024, up to 58 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 520 | $271,900 |
| Return visit (30+ min) | 297 | $501 |
| Short return visit (20+ min) | 99 | $48 |
| Pain severity quantified; no pain present (COA) (ONC) | 141 | $0 |
| Medication list documented in medical record (COA) | 419 | $0 |
| Review of all medications by a prescribing practitioner or clinical pharmacist (such as, prescriptions, OTCs, herbal therapies and supplements) documented in the medical record (COA) | 20 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 499 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 483 | $0 |
| Long return visit (40+ min) | 82 | $0 |
| 2024 | 2,560 | 9 | 58 | $272,449 |
| 2023 | 1,134 | 7 | 64 | $281,079 |
| 2022 | 1,005 | 7 | 67 | $192,302 |
| 2021 | 1,968 | 6 | 73 | $360,005 |
| 2020 | 1,378 | 6 | 71 | $236,994 |
| 2019 | 1,374 | 5 | 93 | $302,099 |
| 2018 | 246 | 2 | 19 | $14,877 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 558 | $280,372 |
| Return visit (30+ min) | 328 | $467 |
| Long return visit (40+ min) | 54 | $125 |
| Short return visit (20+ min) | 134 | $115 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 13 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 26 | $0 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 21 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 386 | $190,931 |
| Short return visit (20+ min) | 217 | $645 |
| Return visit (30+ min) | 115 | $629 |
| Short return visit | 43 | $72 |
| Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only | 12 | $26 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 119 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 113 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 738 | $357,949 |
| Short return visit (20+ min) | 479 | $1,115 |
| Return visit (30+ min) | 184 | $482 |
| Short return visit | 305 | $459 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 130 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 132 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 658 | $235,033 |
| Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only | 103 | $839 |
| Return visit (30+ min) | 128 | $595 |
| Short return visit (20+ min) | 254 | $300 |
| Short return visit | 188 | $227 |
| Telephone evaluation and management service by a physician or other qualified health care professional who may report evaluation and management services provided to an established patient, parent, or guardian not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | 47 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 842 | $300,757 |
| Return visit (30+ min) | 285 | $619 |
| Short return visit (20+ min) | 184 | $327 |
| Long return visit (40+ min) | 50 | $202 |
| Electroencephalogram (EEG) extended monitoring; 41-60 minutes | 13 | $194 |
2018
| Return visit (30+ min) | 141 | $9,706 |
| Short return visit (20+ min) | 105 | $5,171 |
Drugs they prescribed that Part D paid
$1,462
Pharmacies billed $1,462 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 32) in 2024. Too few prescriptions to compare fairly with other clinicians.
32 generic and 0 brand-name prescriptions · $1,462 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Oxcarbazepine | 11 | $620 | $56 |
Year by year
| 2024 | 32 | None | 0% (0) | 0% | $1,462 |
| 2023 | 38 | None | 0% (0) | 0% | $7,352 |
| 2017 | 14 | None | None | None | $560 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Clobazam | 12 | $4,323 | $360 |
| Oxcarbazepine | 12 | $1,724 | $144 |
Money from drug and device companies
$1,617 in 2025
| 2025 | 1 | 11 | None | $1,617 |
| 2020 | 1 | 1 | None | $1,158 |
| 2019 | 4 | 4 | $750 | $1,006 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| LivaNova USA | Vns Therapy | $1,617 | 11 payments
|
See all 11 published payments
| LivaNova USA | Travel · 2025-12-08 | Vns Therapy | $150 |
| LivaNova USA | Meals · 2025-11-21 | Vns Therapy Sentiva Model 1000 Generator | $9 |
| LivaNova USA | Meals · 2025-11-15 | Vns Therapy | $267 |
| LivaNova USA | Travel · 2025-11-14 | Vns Therapy | $387 |
| LivaNova USA | Travel · 2025-11-14 | Vns Therapy | $267 |
| LivaNova USA | Travel · 2025-11-14 | Vns Therapy | $324 |
| LivaNova USA | Meals · 2025-11-14 | Vns Therapy | $175 |
| LivaNova USA | Meals · 2025-11-06 | Vns Therapy Sentiva Model 1000 Generator | $14 |
| LivaNova USA | Meals · 2025-06-26 | Vns Therapy Sentiva Model 1000 Generator | $6 |
| LivaNova USA | Meals · 2025-04-22 | Vns Therapy Sentiva Model 1000 Generator | $12 |
| LivaNova USA | Meals · 2025-04-10 | Vns Therapy Sentiva Model 1000 Generator | $6 |
See earlier years (2020, 2019)
2020: $1,158
| Allergan | Botox Cosmetic | $1,158 | 1 payment
|
2019: $1,006
| Eisai | Fycompa | $750 | 1 payment
|
| Greenwich Biosciences | Epidiolex | $128 | 1 payment
|
| Biogen | Spinraza | $115 | 1 payment
|
| Boston Scientific | General Pain Management | $12 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| UCB Biosciences Inc. · An Open-Label Study To Determine Safety, Tolerability, and Efficacy of Long-Term Oral Lacosamide (Lcm) As Adjunctive Therapy in Children With Epilepsy · 2022 | Their institution | $45,610 |
| UCB Biosciences Inc. · An Open-Label Study To Determine Safety, Tolerability, and Efficacy of Long-Term Oral Lacosamide (Lcm) As Adjunctive Therapy in Children With Epilepsy · 2019 | Their institution | $28,247 |
| UCB Biosciences Inc. · An Open-Label Study To Determine Safety, Tolerability, and Efficacy of Long-Term Oral Lacosamide Lcm As Adjunctive Therapy in Children With Epilepsy · 2020 | Their institution | $21,839 |
| UCB Biosciences Inc. · A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study To Investigate the Efficacy and Safety of Lacosamide As Adjunctive Therapy in Subjects With Epilepsy 1 Month To 4 · 2020 | Their institution | $20,796 |
| UCB Biosciences Inc. · A Multicenter, Open-Label Study To Investigate the Safety and Tolerability of Intravenous Lacosamide in Children 1 Month To 17 Years of Age With Epilepsy · 2020 | Their institution | $18,244 |
| UCB Biosciences Inc. · A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study To Investigate the Efficacy and Safety of Lacosamide As Adjunctive Therapy in Subjects With Epilepsy ?1 Month To <4 Years of Age With Partial-Onset Seizures · 2020 | Their institution | $18,128 |
| UCB Biosciences Inc. · An Open-Label Study To Determine Safety, Tolerability, and Efficacy of Long-Term Oral Lacosamide (Lcm) As Adjunctive Therapy in Children With Epilepsy · 2020 | Their institution | $17,060 |
| UCB Biosciences Inc. · A Multicenter, Open-Label Study To Investigate the Safety and Tolerability of Intravenous Lacosamide in Children (?1 Month To <17 Years of Age) With Epilepsy · 2020 | Their institution | $17,044 |
| Eisai Inc. · An Open-Label, Multicenter Study With An Extension Phase To Evaluate the Safety, Tolerability, and Exposure-Efficacy Relationship of Perampanel Oral Suspension When Administered As An Adjunctive Therapy in Pediatric Subjects (Age 4 To Less Than 12 Years) With Inadequately Controlled Partial-Onset Seizures Or Primary Generalized Tonic Clonic Seizures · 2019 | Their institution | $6,523 |
| UCB Biosciences Inc. · A Multicenter, Open-Label, Long-Term Extension Study To Investigate the Efficacy and Safety of Lacosamide As Adjunctive Therapy in Pediatric Subjects With Epilepsy With Partial Onset Seizures · 2019 | Their institution | $4,659 |
| UCB Biosciences Inc. · A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study To Investigate the Efficacy and Safety of Lacosamide As Adjunctive Therapy in Subjects With Epilepsy >=1 Month To <4 Years of Age With Partial-Onset Seizures · 2019 | Their institution | $4,650 |
| UCB Biosciences Inc. · A Multicenter, Open-Label Study To Investigate the Safety and Tolerability of Intravenous Lacosamide As Replacement for Oral Lacosamide in Children (>=4 To <17 Years of Age) With Epilepsy · 2019 | Their institution | $4,594 |
| Avanir Pharmaceuticals, Inc. · 2019 | Their institution | $2,500 |
Professional record
- NPI
- 1639257264
- Licence
- NV DO1405
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084N0402X (2084N0402X)
- Mailing address
- 2821 W Horizon Ridge Pkwy, Ste. 100, Henderson, NV, 89052
- NPI first listed
- 2006-11-01
- NPI last updated
- 2017-02-23
This is when the NPI record was last certified, not a medical board exam.